(Total Views: 166)
Posted On: 10/02/2019 2:52:03 PM
Post# of 36566
Yet another Keytruda collaboration showing promise. We need to get patients enrolled in our study.
On the stock market today, shares of Seattle Genetics (SGEN) popped 12.4%, to 85.40, in above-average volume. Seattle Genetics stock easily topped a buy point at 81.50, out of a cup with handle that began forming in October 2018.
The biotech company tested a combination of its experimental drug, enfortumab vedotin, and an immuno-oncology drug called Keytruda, from Merck (MRK). Nearly three-quarters of patients, or 71%, responded to the bladder cancer treatment, Seattle Genetics said in a news release.
On the stock market today, shares of Seattle Genetics (SGEN) popped 12.4%, to 85.40, in above-average volume. Seattle Genetics stock easily topped a buy point at 81.50, out of a cup with handle that began forming in October 2018.
The biotech company tested a combination of its experimental drug, enfortumab vedotin, and an immuno-oncology drug called Keytruda, from Merck (MRK). Nearly three-quarters of patients, or 71%, responded to the bladder cancer treatment, Seattle Genetics said in a news release.
(1)
(0)
